Roche's Ocrelizumab On Course As First Drug For Primary Progressive MS
This article was originally published in Scrip
Roche/Genentech's new multiple sclerosis drug ocrelizumab is the first to demonstrate efficacy against primary progressive multiple sclerosis (PPMS), according to data from the pivotal Phase III ORATORIO study. About 1 in ten people with MS are diagnosed with PPMS, and there are currently no drugs approved for the condition.
Register for our free email digests: